Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has experienced significant volatility, with a nearly 15% drop and a more than 40% withdrawal since December 5, following a substantial price increase of 100% over just 10 trading days from November 21 to December 4 [1] Group 1: Stock Performance - The stock price is currently down 11.59%, trading at HKD 4.96, with a trading volume of HKD 6.7798 million [1] - The stock saw a remarkable increase in value, doubling within a short span of 10 trading days [1] Group 2: Company Announcements - Bolekang Vision announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199 to the U.S. Food and Drug Administration on December 15 [1] - CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, which are expected to support future clinical trials [1] Group 3: Investor Information - On January 3, two cornerstone investors of Bolekang Vision will face a lock-up expiration for their shares [1]
拨康视云-B一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请